The New England Journal of Medicine | Research & Review Articles …
WEBThe New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Tirzepatide versus Semaglutide Once Weekly in Patients with Type …
WEBJun 25, 2021 · Tirzepatide is a dual glucose-dependent insulinotropic polypeptide–GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid ...
AI in Medicine | NEJM
WEBMay 29, 2024 · Artificial Intelligence (AI) has tremendous potential to advance clinical practice and the delivery of patient care. A new Review article series, “AI in Medicine,” explores the role of AI ...
Lecanemab in Early Alzheimer’s Disease | NEJM
WEBNov 29, 2022 · Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta (Aβ) protofibrils, which have been shown to be more toxic to neurons than monomers or insoluble ...
Hydrocortisone in Severe Community-Acquired Pneumonia
WEBMar 21, 2023 · Community-acquired pneumonia remains a major public health issue. Worldwide, 489 million lower respiratory infections occurred in 2019. 1 In the United States, more than 1.5 million adults are ...
Empagliflozin in Patients with Chronic Kidney Disease
WEBNov 4, 2022 · We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m 2 of body-surface area, or who had ...
Semaglutide and Cardiovascular Outcomes in Obesity without …
WEBNov 11, 2023 · A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 ...
Beta-Blockers after Myocardial Infarction and Preserved Ejection ...
WEBApr 7, 2024 · From September 2017 through May 2023, a total of 5020 patients were enrolled (95.4% of whom were from Sweden). The median follow-up was 3.5 years (interquartile range, 2.2 to 4.7).
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH …
WEBFeb 7, 2024 · From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National ...
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy …
WEBMar 11, 2023 · Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in 2664 men. Of these...